ストックスクリーナーアプリを入手
14.71
12.23%
-2.05
プレマーケット:
14.80
0.09
+0.61%
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - BioSpace
What drives Arrowhead Pharmaceuticals Inc. stock priceFree Stock Market Return Analysis - Autocar Professional
What analysts say about Arrowhead Pharmaceuticals Inc. stockExceptional profit velocity - Autocar Professional
Arrowhead (ARWR) Stock Drops Over 11%, Significant Decline Noted - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Falls Amid Sarepta FDA Issues - GuruFocus
Arrowhead Pharmaceuticals Plummets 9.4%: A Bearish Surprise in Biotech's RNAi Frontier - AInvest
Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional
Is Arrowhead Pharmaceuticals Inc. a good long term investmentExceptional growth trajectory - jammulinksnews.com
Insiders At Arrowhead Pharmaceuticals Sold US$3.1m In Stock, Alluding To Potential Weakness - simplywall.st
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia - TipRanks
Arrowhead Pharmaceuticals (ARWR) Soars 7.64% on Clinical Trial Advances - AInvest
Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management - TipRanks
Arrowhead Pharmaceuticals' Zodasiran: A Pioneering ANGPTL3 Inhibitor for HoFH and Beyond - AInvest
Arrowhead Pharmaceuticals initiates phase 3 Yosemite study of investigational zodasiran - MarketScreener
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire
Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse - The Globe and Mail
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire
Where are the Opportunities in (ARWR) - news.stocktradersdaily.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada
California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey
Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire
Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com
What is HC Wainwright’s Estimate for ARWR FY2025 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead at RBC Conference: Strategic Insights on Drug Pipeline By Investing.com - Investing.com India
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):